patient population was similar to the Weidmann's study: 150 cases were included and CHOP drugs were given in decreased doses (nearly half of the original CHOP regimen) with standard-dose rituximab. So, the most important problematic drug doxorubicin was given 25 mg/m 2 . When we looked at the toxicity profile, grade III-IV neutropenia and thrombocytopenia were found in 40% and 7% of the cases, respectively. This toxicity is manageable with granulocyte colony-stimulating factor. Overall response rate was 74%: 40% CR, 23% unconfirmed CR, 11% PR, and disease progression developed in only 5% of the cases. Median PFS was 21 months and 2-year PFS was 47%. GELA investigators suggested that R-mini-CHOP is the new standard treatment in cases with DLBCL >80. The other important point is the cost of the drugs used in clinical practice. Bendamustine is an expensive drug. Table 1 compares the efficacy, toxicity and cost of these two regimens. In summary, BR regimen has mild efficacy but high cost and toxicity in aggressive lymphomas. R-mini-CHOP is an important candidate regimen for elderly cases with DLBCL both for efficacy and for cost-effectiveness. 
